Barton P. Bandy Sells 12,565 Shares of ReShape Lifesciences Inc. (OTCMKTS:RSLS) Stock

ReShape Lifesciences Inc. (OTCMKTS:RSLS) CEO Barton P. Bandy sold 12,565 shares of the company’s stock in a transaction that occurred on Friday, October 1st. The stock was sold at an average price of $2.77, for a total transaction of $34,805.05. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Barton P. Bandy also recently made the following trade(s):

  • On Friday, September 10th, Barton P. Bandy sold 294,494 shares of ReShape Lifesciences stock. The stock was sold at an average price of $2.89, for a total transaction of $851,087.66.

Shares of RSLS stock opened at $2.83 on Thursday. The firm has a 50-day moving average of $3.08 and a 200-day moving average of $2.90. The company has a market cap of $44.83 million, a P/E ratio of -0.98 and a beta of -1.30. ReShape Lifesciences Inc. has a one year low of $2.16 and a one year high of $32.31.

ReShape Lifesciences (OTCMKTS:RSLS) last posted its earnings results on Monday, August 16th. The medical device company reported ($0.15) earnings per share for the quarter. ReShape Lifesciences had a negative return on equity of 42.08% and a negative net margin of 776.76%. The business had revenue of $3.53 million during the quarter.

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. purchased a new position in shares of ReShape Lifesciences in the second quarter worth $256,000. Geode Capital Management LLC purchased a new position in ReShape Lifesciences during the 2nd quarter valued at $116,000. Alpine Global Management LLC purchased a new position in ReShape Lifesciences during the 2nd quarter valued at $85,000. State Street Corp bought a new stake in shares of ReShape Lifesciences during the 2nd quarter valued at $550,000. Finally, Armistice Capital LLC bought a new stake in shares of ReShape Lifesciences during the 2nd quarter valued at $4,083,000. Institutional investors and hedge funds own 66.58% of the company’s stock.

A number of equities research analysts have recently commented on RSLS shares. Maxim Group started coverage on shares of ReShape Lifesciences in a research note on Friday, October 8th. They issued a “buy” rating and a $8.00 price objective on the stock. Alliance Global Partners reissued a “buy” rating and set a $10.25 target price (down from $13.75) on shares of ReShape Lifesciences in a research note on Friday, August 20th.

ReShape Lifesciences Company Profile

ReShape Lifesciences, Inc operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. It operates through the following segments: Lap-Band, ReShape Vest and ReShapeCare and Diabetes Bloc-Stim Neuromodulation Device. The company is headquartered in San Clemente, CA.

Featured Article: Why are analyst ratings important in trading stocks?

Insider Buying and Selling by Quarter for ReShape Lifesciences (OTCMKTS:RSLS)

Receive News & Ratings for ReShape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReShape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.